To evaluate the effects of an aldosterone antagonist on exercise intolerance in older adults with heart failure and preserved ejection fraction (HFpEF). DESIGN: Randomized, placebo-controlled, double-blind trial. SETTING: Academic medical center, Winston-Salem, North Carolina. PARTICIPANTS: Older adults (N = 80, aged 71 AE 1; 80% female) with stable compensated HFpEF and controlled blood pressure (BP). MEASUREMENTS: Participants were randomized into a 9-month treatment of spironolactone 25 mg/d vs placebo. Assessments were peak exercise oxygen consumption (VO 2 ), 6-minute walk test, Minnesota Living with Heart Failure Questionnaire (MLHFQ), cardiac magnetic resonance imaging, Doppler echocardiography, and vascular ultrasound. RESULTS: Seventy-one participants completed the trial: 37 in the spironolactone group and 34 in the placebo group. Adherence according to pill count was excellent (spironolactone 95%, placebo 97%). Mean spironolactone dose was 24.3 AE 2.9 mg/d and was well tolerated. Spironolactone significantly reduced systolic and diastolic BP at rest and peak exercise. At 9-month follow-up, baseline-adjusted peak VO 2, the primary outcome, was 13.5 AE 0.3 mL/kg per minute in the spironolactone group versus 13.9 AE 0.3 mL/kg per minute in the placebo group (adjusted mean difference À0.4 mL/kg per minute; 95% confidence interval = À1.1-0.4 mL/kg per minute; P = .38). The 95% confidence intervals of spironolactone's effect on peak VO 2 (À8.2% to 3.2%) excluded a clinically significant beneficial effect. There were also no significant differences in 6-minute walk distance, arterial stiffness, left ventricular (LV) mass, LV mass/end-diastolic volume, or MLHFQ score. CONCLUSION: In older adults with stable compensated HFpEF, 9 months of spironolactone 25 mg/d was well tolerated and reduced BP but did not improve exercise capacity, quality of life, LV mass, or arterial stiffness. J Am Geriatr Soc 65:2374-2382, 2017.
H eart failure (HF) with preserved ejection fraction (EF) (HFpEF) is nearly exclusively found in older adults, particularly older women, in whom 90% of new HF cases are HFpEF. 1 In contrast to HF with reduced EF (HFrEF), the prevalence of HFpEF is increasing, and its prognosis is worsening. 1 Exercise intolerance, manifested by dyspnea and fatigue during exertion, is the primary chronic symptom that individuals with HF have 1, 2 and can be quantified objectively and reliably by measuring peak exercise oxygen consumption (VO 2 ).
2, 3 The reduction in peak VO 2 in individuals with HFpEF is similar in severity to that in individuals with HFrEF, 2 but this clinically meaningful outcome has received much less attention than clinical endpoints in the quest for HFpEF treatments.
Several lines of evidence suggest that aldosterone excess could contribute to exercise intolerance in individuals with HFpEF. Serum aldosterone levels are high in individuals with HFpEF, and it promotes vascular inflammation; arterial stiffness; and left ventricular (LV) hypertrophy, fibrosis, and stiffness. 4, 5 Arterial stiffness increases with age, is inversely correlated with age-related decline in exercise capacity, and is further accelerated by hypertension, a common precursor to HFpEF. 6 The aorta and carotid artery are stiff in elderly adults with HFpEF, and their stiffness is strongly correlated with low peak VO 2 . 7 Aldosterone antagonism with spironolactone improves exercise intolerance and aortic stiffness in individuals with HFrEF. 8 In rats with hypertension, aldosterone antagonism decreases myocardial collagen volume, improves LV concentric remodeling, and decreases diastolic stiffness. 9 In a published open-label pilot study of individuals with HFpEF, spironolactone therapy was associated with improvements in peak VO 2 , echo-Doppler measures of diastolic function, and New York Heart Association (NYHA) class. 10 It was hypothesized that the severe exercise intolerance that older adults with HFpEF experience can be improved using an aldosterone antagonist and that improvements in arterial distensibility would at least partly mediate this improvement. To test this hypothesis, a 9-month prospective, randomized, double-blind, placebocontrolled trial was performed with detailed measurements of exercise performance, health-related quality of life, and cardiac and vascular structure and function.
METHODS

Study Design
The Wake Forest School of Medicine institutional review board approved the study protocol. Written informed consent was obtained. All tests were performed in a postabsorptive state with medications except for the study medication held for 12 hours before testing. Testing was performed at baseline and repeated after 4 and 9 months, except cardiac magnetic resonance imaging (CMRI), which was repeated only at 9 months. The research pharmacy prepared and distributed placebo and active drug using a secure methodology. All investigators, staff, and participants were fully blinded to treatment group assignment throughout the study period; during data abstraction, cleanup, and image analyses; and until the database had been locked. Eligible individuals were randomly assigned to receive spironolactone (25 mg/d) or matching placebo. Adherence was assessed according to pill count. The starting dose of spironolactone was 12.5 mg/d in individuals with baseline creatinine of 2.0 mg/dL or greater or potassium greater than 4.5 mEq/L; in all other participants, the starting dose was 25 mg/d. In participants who initiated therapy with the 12.5-mg/d dose, the dose was increased to 25 mg/d once creatinine fell below 2.5 mg/dL and potassium fell below 5.0 mEq/L and maintained at that dosage as long as those levels were maintained. Spironolactone was discontinued if 1-week creatinine was 2.5 mg/ dL or higher or potassium was 5.0 mEq/L or higher. To ensure safety, adherence, and retention in the study, participants were seen in clinic or contacted over the telephone regularly.
Participants
As previously described, and in accordance with the 2013 American College of Cardiology (ACC) Guideline for Evaluation and Management of HF, HFpEF was defined as history, symptoms, and signs of HF, a preserved LVEF of 50% or greater and no evidence of other medical condition that could mimic HF symptoms. 2, 7, [11] [12] [13] [14] [15] [16] Coronary disease was excluded according to history, medical record, electrocardiogram, and rest and exercise echocardiogram. Diagnosis of HF was based on clinical criteria as previously described and included a HF clinical score from the National Health and Nutrition Examination Survey (NHANES) of 3 or greater 17 and criteria used in a previous study 18 and verified by a board certified cardiologist. 13, 15 The NHANES criteria have been shown to have 94% specificity for HF, similar to the traditional Framingham criteria. 19 Exclusions included aldosterone antagonist use within the previous 3 months, a known contraindication, concomitant therapy with a potassium-sparing diuretic or potassium supplementation, baseline serum potassium level greater than 5.0 mEq/L, or serum creatinine level of 2.5 mg/dL or greater.
Outcome Measures
Exercise Performance
Exercise testing was performed as previously described, with participants in the upright position on an electronically braked bicycle. 2, 7, 12, 16, 16 Expired gas was analyzed using a metabolic cart calibrated with a standard gas of known concentration and volume. Metabolic gas exchange was measured continuously during exercise and averaged over 15-second intervals. Peak values were averaged from the final 30 seconds of the exercise test. A 6-minute walk test was performed as described previously. 20 Aortic Distensibility and LV Structure and Function CMRI scans were performed on a 1.5T Avanto scanner (Siemens Medical Solutions, Erlangen, Germany) with a phased-array surface coil applied to optimize signal to noise. Multislice coronal, gradient-echo sequences were used to obtain scout images of the chest to locate the heart and aorta. After the aorta was located, a series of sagittal and axial images in standard and oblique planes was obtained. Assessment of aortic distensibility was then defined and calculated according to previously published techniques. 7, 21 As previously described, LV volume and mass were assessed from a series of multislice, multiphase gradientecho sequences positioned perpendicular to the long axis of the left ventricle (short-axis), spanning apex to base. 7, 21 For LV volume and mass determinations, the epi-and endocardial borders of each slice were traced manually at end diastole and end systole, and volumes were calculated by summation (Simpson's rule). 7, 21 LV stroke volume and EF were calculated from standard formulas.
Carotid Artery Stiffness
As described previously, 22 standardized longitudinal B-mode images of the left common carotid artery (LCA) were recorded with the subject in the supine position. Mean, maximum, and minimum arterial diameter, lumen diameter, and wall thickness were then computed from each image, and carotid artery stiffness indexes were calculated using standard equations.
Pulse Wave Velocity
Pulse wave velocity (PWV) measured using the Doppler method with two-dimensional guidance was analyzed, with regional Doppler PWV defined as the distance between the extremities of a given segment divided by the transit time calculated using Doppler. 23 The examination began with the participant in a supine position after the LCA was located using B-mode at the supraclavicular level. The Doppler wave flow was then simultaneously identified using electrocardiography. The process was repeated on the left femoral artery in the groin.
LV Diastolic Filling
Mitral annulus tissue and blood flow Doppler were performed using an ultrasound imaging system with a multiple frequency transducer. Doppler tracings were then analyzed using a digital echocardiography workstation, as previously described.
2,21,24
Quality of Life
The Minnesota Living with Heart Failure Questionnaire (MLHFQ), a HF-specific measure, was administered to assess the effect of the intervention on quality of life.
2,25
Statistical Analysis
The study was designed to test for the effect of spironolactone on two primary outcome measures: peak VO 2 and total MLHFQ score. The sample size was derived from a formal power analysis using data from previously published studies and from a pilot study conducted specifically to inform the design of the present trial. 10 These data indicated that a final sample size of 60 evaluable participants at the end of the study (72 participants randomized at the beginning of the study and assuming up to 15% dropout during 9 month of follow-up) would provide 94% power to detect a 5% change in peak exercise VO 2 and 90% power to detect a 20% change in total MLFHQ score.
Group comparisons of outcome measures between intervention groups were made using repeated-measures analysis of covariance (ANCOVA) procedures. For the CMRI outcome measures, comparisons between intervention groups were made using ANCOVA. To reduce bias and increase precision, the analyses were adjusted for prerandomization values of the outcome measure being considered as well as other factors (age, sex) significantly associated with the outcome variable after adjusting for the other terms in the model. 26 The values of the non-CMRI outcome measures taken at 4 and 9 months were considered the repeated measures. A test of the group-by-time interaction was used to check the consistency of any intervention effect at each of the two endpoint evaluations (4 and 9 months). If the interaction was nonsignificant at the .10 level of significance, then the overall effect of the intervention over the experimental period was estimated. Data are presented as raw, unadjusted means and standard deviations at each visit for each group, along with the P-value corresponding to the adjusted leastsquares outcomes means from the ANCOVA procedures accounting for all data at all follow-up visits. Significance was set at P < .05.
RESULTS
Participants were recruited using a staged screening process; 4,035 charts were selected using electronic search criteria and reviewed, 546 of those individuals were contacted and screened over the telephone, and 142 of those were scheduled for a screening clinic visit. Eighty individuals were enrolled in the trial: 42 randomized to spironolactone and 38 randomized to placebo. There were no significant differences between the treatment groups in age, sex, race, weight, EF, or NYHA class (Table 1) .
Adherence, Adverse Events, and Retention
Adherence was excellent in both groups (spironolactone 95%; placebo 97%). Eight participants (10%) received less than the full dose or were down-titrated (6 spironolactone; 2 placebo). Of the six down-titrated participants in the spironolactone group, two were increased back to full dose within 1 week, two eventually dropped out of the study, and two finished at less than full dose. The total daily final dose was 12.5 mg in both cases. The mean daily dose of spironolactone was 24.3 AE 2.9 mg/d. The most-common reasons for not achieving full dose were high potassium levels and a decrease in resting BP. Thirty-seven participants randomized to spironolactone and 35 randomized to placebo completed 4 months of follow-up, and 37 participants randomized to spironolactone and 34 randomized to placebo completed 9 months of follow-up. Of the nine participants not represented in the 9-month follow-up data, eight dropped out, and one died (car crash in the placebo group). The dropouts were because of participant request (n = 7) and high potassium level (n = 1). According to the blinded investigators, only the last was judged to be possibly related to study medication and occurred in the spironolactone group Twenty-three minor adverse events occurred during the study period (12 spironolactone, 11 placebo). According to the blinded investigators, one event that occurred was judged possibly related to study medication (high potassium). There were 16 hospitalizations during the study (3 chest pain (myocardial infarction excluded for all) (2 spironolactone, 1 placebo), 5 shortness of breath (placebo), 2 syncopal episodes (spironolactone), 1 hypotension (spironolactone), 1 self-limited angioedema (spironolactone), 4 elective surgery (2 broken bones, 1 torn rotator cuff, 1 gall bladder surgery) (1 spironolactone, 3 placebo)).
Exercise Performance
Participants gave an exhaustive effort at baseline and follow-up testing, as evidenced by a mean respiratory exchange ratio (RER) greater than 1.10, and there was equal effort between the groups, as shown by no significant difference in RER values (Table 2) . At baseline, peak exercise VO 2 was much lower in both groups than expected for age (Table 2 ). There was no significant difference in baseline-adjusted 9-month follow-up mean peak VO 2 values (13.5 AE 0.3 spironolactone, 13.9 AE 0.3 placebo, À0.4 mL/kg per minute less with spironolactone; 95% confidence interval (CI) = À1.1-0.4 mL/kg per minute, P = .38) ( Table 2 ). The estimated treatment effect size on peak exercise VO 2 was À0.4 AE 0.4 mL/kg per minute (95% CI = À1.1-0.4 mL/kg per minute; À2.5%, 95% CI = À8.2-3.2%), essentially excluding potential for a clinically meaningful effect. There were no significant differences between the groups in any other measure of peak exercise capacity or in any measure of submaximal exercise performance.
Quality of Life
No significant difference was seen in total MLHFQ score between the spironolactone and placebo groups (P = .81; Table 2 ).
LV Structure and Function
There were no significant differences in any Doppler LV diastolic function variables (Table 3 ) between the two groups. According to CMRI, there were no differences during follow-up in LV mass, LV volume, EF, or the ratio of LV mass to end-diastolic volume, a measure of concentric LV remodeling (Table 4) .
Arterial function
Aortic distensibility according to CMRI, the primary mechanistic outcome, was not significantly different between groups during follow-up. Similarly, neither carotid distensibility nor PWV according to ultrasound were significantly different between groups during follow-up (Table 4) .
Neurohormones
Serum aldosterone was significantly higher in the spironolactone group (17.2 AE 8.6 ng/dl) than in those receiving placebo (9.7 AE 5.3 ng/dl) (P < .001), but B-type natriuretic peptide (BNP) remained same ( Table 2) .
DISCUSSION
This randomized, placebo-controlled, double-blind study examined the potential benefit of 9 months of treatment with the aldosterone antagonist spironolactone to improve exercise tolerance and quality of life in individuals with HFpEF, as well as measures of arterial stiffness that are thought to contribute to the pathophysiology of this disorder. At baseline, participants had stable, compensated HFpEF, controlled BP, and a severe lack of exercise capacity. Contrary to the primary hypothesis, there was no difference in peak or submaximal exercise capacity, quality of life according to the MLHFQ, arterial function, or LV mass/volume.
In individuals with HFrEF and those with myocardial infarction complicated by LV dysfunction, aldosterone antagonists are effective in reducing overall mortality and hospitalizations for HF. [27] [28] [29] This is in contrast to the trials (Table 5 ). In the large Treatment of Preserved Cardiac Function Heart Failure with an Aldosterone Antagonist Trial (TOPCAT), 32 the overall effect of spironolactone was neutral on clinical endpoints (survival, cardiovascular events, hospitalizations), although there appeared to be a strong, divergent response depending on geography and disease severity. 32, 33 It was also noted TOPCAT that the potential efficacy of spironolactone was greatest at the lower end of the LVEF spectrum. 34 P-value represents comparison of least square means at combined follow-up visits after adjustment for baseline values, age, and sex. Logarithmic transformation was used for nonnormally distributed variables that were highly skewed. VO 2 = oxygen consumption; VCO 2 = carbon dioxide production; VE = volume of gas inhaled or exhaled per minute. The results of the current study are consistent with those of two prior trials examining the effect of aldosterone antagonists on exercise function in individuals with HFpEF. In the Randomized Aldosterone Antagonism in Heart Failure with Preserved Ejection Fraction Trial (RAAM-HF) single-center trial, there were no significant treatment-related differences in 6-minute walk distance (6-MWD), the primary outcome, or quality of life, despite improvements in levels of procollagen type I amino terminal peptide, a fibrosis biomarker, and E/e', a Doppler measure of diastolic function. 30 Similarly, in the ALDOsterone receptor blockade in Diastolic Heart Failure Trial (ALDO-DHF) multicenter trial, although E/e' and LV remodeling improved, there was no treatment-related difference in peak VO 2 , the co-primary outcome, or 6-MWD. 31 Combining the current study with RAAM-HF and ALDO-DHF provides 546 randomized individuals with HFpEF in three randomized, controlled, blinded trials using two different aldosterone antagonists, all showing no treatment-related improvement in the outcome of exercise capacity. (Two measured peak VO 2 , and all three measured 6-MWD.) Furthermore, the confidence limits of the effect size in the current trial alone exclude the potential for a clinically meaningful effect on peak VO 2 (≥0.5 mL/ kg per minute), the most-rigorous measure of exercise capacity in individuals with HF. 35 Results that differ from those of the above three studies were recently reported. In individuals with exertional dyspnea, diastolic dysfunction, and a high noninvasively estimated LV diastolic filling pressure (measured as exercise E/ e 0 ratio) during exercise, the addition of spironolactone to existing therapy for 6 months was associated with greater exercise capacity, and this appeared to be associated with improved LV filling pressure. 36 It is possible that selection of individual on the basis of exercise-induced increase in E/e 0 might have helped to select the particular HFpEF phenotype that is most likely to be responsive to spironolactone.
The current study extends previously published data in several ways. Participants were approximately 5 years older than in previous studies, and the proportion of women was larger, so participant demographic characteristics were more similar to those reported in population-based studies. 1 In addition, a robust, novel means of exercise testing was used that included ventilatory anaerobic threshold, which is a measure of submaximal exercise capacity. This may be most relevant in older persons who infrequently undertake physical activity at the level of exhaustive exercise. It had been shown before that submaximal and peak exercise test variables in the protocol had good reliability and that a learning effect or placebo administration did not significantly alter them. Furthermore, CMRI, which has been shown to be much more sensitive to change in LV mass than echocardiography, was used. 37 Aortic distensibility was also examined using CMRI, and arterial stiffness was measured using ultrasound. Arterial stiffness is markedly lower in older adults with HFpEF and is strongly correlated with their lower peak VO 2 , 7, 38 and others have shown that it is an important determinant of LV afterload and ventricular-vascular coupling. 7 Spironolactone had been shown to reduce aortic stiffness in individuals with resistant hypertension, 39 diabetes mellitus, 40 and early-stage kidney disease. 41 Previous trials have shown that neither enalapril nor alagebrium improves aortic distensibility or exercise capacity in older adults with HFpEF. 13, 21 It is possible that the severe aortic and arterial stiffness in older adults with HFpEF may have limited potential for reversibility given that it is likely that it develops over many years and has multiple causes. 6 It is uncertain why aldosterone antagonism has not improved exercise capacity in most studies of HFpEF, but aldosterone antagonists may not substantially improve symptoms in individuals with HFrEF, despite their ability to increase survival and decrease HF hospitalizations. 29, 42 As occurred in ALDO-DHF, significant reductions in rest and exercise systolic and diastolic BP were observed, 31 which would have been expected to produce favorable effects on LV afterload, ventricular-vascular coupling, and LV relaxation. Mechanistic studies of exercise intolerance in individuals with HFpEF (and HFrEF) indicate that exercise intolerance in HF is multifactorial and a complex interaction of cardiac, peripheral vascular, and skeletal muscle factors, including abnormal skeletal muscle composition and function, [43] [44] [45] [46] the last of which aldosterone antagonism might not be expected to influence. 44, 47 Limitations By design, participants were outpatients with stable, wellcompensated HFpEF who were able to participate in exhaustive exercise testing and long-term follow-up. As a result, mean BNP was less than in individuals with acute, decompensated HF, although BNP levels were similar to those in other studies of individuals with stable HFpEF able to undergo maximal exercise testing, 13,48-51 including a previous study (which were slightly lower than ours), 36 and are several times as high as in healthy, age-matched, normal subjects. 2 Current study participants had abnormalities in ventilatory efficiency (V E /VCO 2 ), a measure of disease severity and prognosis, and in peak VO 2 at baseline that were similar in degree to those found in other studies of aldosterone antagonism in HFpEF. 30, 31 Nevertheless, the results may not apply to individuals with more-severe disease and more comorbidities. The possibility cannot be excluded that an even longer duration of treatment or higher aldosterone antagonist dose would improve exercise capacity, although the ALDO-DHF trial treatment duration was 12 months. The current study used the ACC, American Heart Association criteria for HFpEF, with confirmation of HF using the NHANES criteria and criteria from a previous study. 18 Other studies of spironolactone that used the European HFpEF criteria, which have specific thresholds for measures from echocardiography and blood tests, have also had neutral outcomes. 31 Because the current study did not assess postexercise Doppler measures of LV filling in the fashion of one of the previous studies, 36 it is unclear whether selection of similar individuals would have shown more-favorable results for spironolactone. HFpEF syndrome is heterogeneous, and it has been speculated that this may have contributed to challenges in the quest for successful therapy. High standard errors of the mean of the CMRI measures were observed in the current study because of small sample size and might have affected overall results. In addition, the applicability of the results to subjects with different HFpEF phenotypes is uncertain. Acknowledging these factors and the resulting phenotypes in designing HFpEF trials could help achieve more-homogenous study populations and thereby better match underlying pathophysiology with proposed therapeutic mechanisms.
CONCLUSION
Nine months of treatment with spironolactone did not improve exercise capacity; quality of life; arterial stiffness; or LV mass, remodeling, or diastolic function in older adults with stable, compensated HFpEF and controlled BP.
